Biopartnering Seminar - Point-of-Care Testing, A Road Map Starting from CD4 Testing

Tuesday, March 14, 2017 - 6:30pm

Point-of-Care Testing, A Road Map Starting from CD4 Testing - Lu Chen, Director of Research, Chipcare Corp

Abstract:
Point-of-Care testing, by its name means the tests that are conducted at the place of patient care. Globally, the market is growing rapidly. Its increase popularity is based on its great fit with the shifting of healthcare mentality toward prevention, disease early detection and management of multiple chronic conditions. While point-of-care testing may be a nice to have technology in developed countries, it can be an indispensable tool to provide needed care to patients in low and middle income countries who otherwise has poor or no access to required care. Point-of-care CD4 testing is a good example. How is such a testing developed? And what can eventually make such a testing beneficial to the patients?

Bio:
Lu Chen grew up in China. After received his B.SC. from Peking University. He came to Canada to pursue his M.Sc. study at Queen's University. He later attended University of Toronto and obtained his Ph.D. in chemistry under supervision of Professor Ulrich Krull. During his post doctoral work at Stewart Aitchson's group, Lu co-developed which later became ChipCare’s core technology. Lu has great interest in technology development in the point-of-care field and has over 10 years of experience in research and development in microfluidics design and product development. In 2012, he received Stars in Global Health from Grand Challenges Canada. He is now Director of Research at ChipCare Corp, a startup company making point-of-care device for blood testing.